Tang Y, Zhou Z, Yan H, You Y
Front Immunol. 2022; 13:810284.
PMID: 35185899
PMC: 8847388.
DOI: 10.3389/fimmu.2022.810284.
Aureli A, Marziani B, Sconocchia T, Del Principe M, Buzzatti E, Pasqualone G
Cancers (Basel). 2021; 13(24).
PMID: 34944865
PMC: 8699368.
DOI: 10.3390/cancers13246246.
Bewersdorf J, Stahl M, Zeidan A
Expert Rev Anticancer Ther. 2019; 19(5):393-404.
PMID: 30887841
PMC: 6527485.
DOI: 10.1080/14737140.2019.1589374.
Merryman R, Armand P
Curr Hematol Malig Rep. 2017; 12(1):44-50.
PMID: 28155012
DOI: 10.1007/s11899-017-0362-5.
Davids M, Kim H, Bachireddy P, Costello C, Liguori R, Savell A
N Engl J Med. 2016; 375(2):143-53.
PMID: 27410923
PMC: 5149459.
DOI: 10.1056/NEJMoa1601202.
Vaccination strategies in lymphomas and leukaemias: recent progress.
Rezvani K, de Lavallade H
Drugs. 2011; 71(13):1659-74.
PMID: 21902290
DOI: 10.2165/11593270-000000000-00000.
Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation.
Ho V, Vanneman M, Kim H, Sasada T, Kang Y, Pasek M
Proc Natl Acad Sci U S A. 2009; 106(37):15825-30.
PMID: 19717467
PMC: 2747203.
DOI: 10.1073/pnas.0908358106.
Characterizing and optimizing immune responses to leukaemia antigens after allogeneic stem cell transplantation.
Rezvani K, Barrett A
Best Pract Res Clin Haematol. 2008; 21(3):437-53.
PMID: 18790448
PMC: 3757471.
DOI: 10.1016/j.beha.2008.07.004.
Manipulating the immune system for anti-tumor responses and transplant tolerance via mixed hematopoietic chimerism.
Gibbons C, Sykes M
Immunol Rev. 2008; 223:334-60.
PMID: 18613846
PMC: 2680695.
DOI: 10.1111/j.1600-065X.2008.00636.x.
Translational mini-review series on vaccines: Peptide vaccines for myeloid leukaemias.
Barrett A, Rezvani K
Clin Exp Immunol. 2007; 148(2):189-98.
PMID: 17437417
PMC: 1868869.
DOI: 10.1111/j.1365-2249.2007.03383.x.
T cell receptor-transgenic primary T cells as a tool for discovery of leukaemia-associated antigens.
Ivanov R, Hol S, Aarts T, Hagenbeek A, Ebeling S
Clin Exp Immunol. 2005; 143(1):78-84.
PMID: 16367937
PMC: 1809573.
DOI: 10.1111/j.1365-2249.2005.02967.x.
Update on non-myeloablative stem cell transplantation for hematologic malignancies.
Giralt S
Int J Hematol. 2002; 76 Suppl 1:176-83.
PMID: 12430850
DOI: 10.1007/BF03165241.
Effects of mixed chimerism and immune modulation on GVHD, disease recurrence and survival after HLA-identical marrow transplantation for hematologic malignancies.
Park S, Min W, Yang I, Kim H, Min C, Eom H
Korean J Intern Med. 2001; 15(3):224-31.
PMID: 11242811
PMC: 4531771.
DOI: 10.3904/kjim.2000.15.3.224.
Treatment of chronic myelogenous leukaemia.
Simonsson B
Med Oncol. 1998; 15(1):27-31.
PMID: 9643527
DOI: 10.1007/BF02787341.
Characterization of T cell repertoire in patients with graft-versus-leukemia after donor lymphocyte infusion.
Claret E, Alyea E, Orsini E, Pickett C, Collins H, Wang Y
J Clin Invest. 1997; 100(4):855-66.
PMID: 9259585
PMC: 508258.
DOI: 10.1172/JCI119601.
Overview of the role of hematopoietic growth factors in bone marrow transplant recovery and bone marrow transplant failure.
Nemunaitis J
Support Care Cancer. 1994; 2(6):374-6.
PMID: 7858929
DOI: 10.1007/BF00344050.
Allogeneic marrow transplantation for chronic myeloid leukemia.
Applebaum F, Clift R, Buckner C, Anasetti C, Radich J, Higano T
Med Oncol. 1994; 11(2):69-74.
PMID: 7850266
DOI: 10.1007/BF02988833.
Case report of spontaneous remission of cytogenetic relapse of chronic myelogenous leukemia suggestive of progression to blast crisis after allogeneic bone marrow transplantation.
Agaliotis D, Papenhausen P, Moscinski L, Elfenbein G
Ann Hematol. 1995; 70(1):37-41.
PMID: 7827205
DOI: 10.1007/BF01715380.
Immunodominant minor histocompatibility antigens expressed by mouse leukemic cells can serve as effective targets for T cell immunotherapy.
Pion S, Fontaine P, Baron C, Gyger M, Perreault C
J Clin Invest. 1995; 95(4):1561-8.
PMID: 7706462
PMC: 295646.
DOI: 10.1172/JCI117829.
Graft-versus-leukemia and graft-versus-lymphoma effects of allogeneic bone marrow transplantation and of allogeneic donor leukocyte transfusions.
Vandenberghe P, Boogaerts M
Ann Hematol. 1995; 71(5):209-17.
PMID: 7492623
DOI: 10.1007/BF01744370.
